A comprehensive study of Industry Dynamics and Competitive Landscape in the Bispecific Antibody Industry From 2023 to 2032
Allied Market Research published a report on the bispecific antibody market, which includes a detailed study of the competitive landscape and regional analysis. This report also provides information about industry dynamics, which includes opportunities, challenges, and growth drivers. The global bispecific antibody industry accounted for $5.5 billion in 2022 and is expected... moreA comprehensive study of Industry Dynamics and Competitive Landscape in the Bispecific Antibody Industry From 2023 to 2032
Allied Market Research published a report on the bispecific antibody market, which includes a detailed study of the competitive landscape and regional analysis. This report also provides information about industry dynamics, which includes opportunities, challenges, and growth drivers. The global bispecific antibody industry accounted for $5.5 billion in 2022 and is expected to grow to $109.4 billion by 2032, reaching a CAGR of 34.8% from 2023 to 2032.
Key industry players
Amgen Inc., Pfizer Ltd
Bristol-Myers Squibb Company
Merus
AbbVie Inc
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals, Inc.
MacroGenics Inc.
AstraZeneca plc
Important questions and answers
Which are the leading companies in the bispecific antibody industry?
What is the fastest-growing region in this sector?
What are the key trends in this domain?
Which is the base year calculated in the bispecific antibody industry?
How many bispecific antibody companies are profiled in the report?
Growth drivers
The growing number of cancer and autoimmune disease increases the need for new treatment options, which surges the importance of bispecific antibodies in treating conditions with limited medical options. Cancer and autoimmune diseases create major difficulties for both patients and healthcare systems around the world, leading to a strong need for better treatments. Bispecific antibodies offer a promising option as they target two different disease markers simultaneously, which makes treatment more effective.
The bispecific antibodies industry is expected to grow quickly by the advancements in immune system research and improvements in biotechnology. One of the main reasons for this growth is increasing use of bispecific antibodies in cancer treatment. These new treatments are designed to specifically target different types of cancer, which is likely to help patients to feel better and recover faster. Bispecific antibodies are helpful for not only cancer but are also used to treat other health problems such as infectious diseases, neurodegenerative disorders, and autoimmune diseases. Their ability to target more than one disease pathways makes them a strong option for treating different health conditions.
Partnerships and collaborations between academic institutions, pharmaceutical companies, and biotechnology firms are supporting the growth of bispecific antibodies in healthcare. These partnerships and collaborations utilize different strengths and resources to discover new treatments effectively.
Regional analysis
The bispecific antibody industry in North America is expected to grow in the coming years, with rise in cancer cases due to lifestyle changes such as a lack of physical activity and smoking. Also, many companies in the region are involved in making bispecific antibodies, which contribute to the growth of this industry. Moreover, the Asia-Pacific region is also expected to grow in the coming years due to the rise in chronic diseases such as autoimmune diseases and cancer. This factor drives the demand for bispecific antibodies for treatment purposes, which boosts the growth of the industry.
Recent developments
In January 2025, Biocytogen announced a partnership with Acepodia to jointly analyze a dual payload bispecific antibody-drug conjugate (BSAD2C) program. This partnership combines Biocytogen’s RenLite platform and Acepodia’s AD2C technology to address major challenges in cancer treatment, like drug resistance and tumor heterogeneity.
In October 2024, ImmunoPrecise announced a partnership with Biotheus on bispecific antibodies to treat cancer. The agreement aims to develop a new bispecific antibody treatment for hypoxic solid tumors, using Talem Therapeutics’ lead drug candidate, TATX-20.
Conclusion
In summary, the AMR report provides an in-depth analysis of industry dynamics, including opportunities, challenges, and growth drivers. This report also offers an overview of industry segmentation and a competitive landscape, which is expected to help industry leaders and stakeholders in strategic decision-making and analyzing industry trends.
